GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Revenue per Share

Ainos (AIMD) Revenue per Share : $0.02 (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Ainos Revenue per Share?

Ainos's revenue per share for the three months ended in Mar. 2024 was $0.00. Ainos's revenue per share for the trailing twelve months (TTM) ended in Mar. 2024 was $0.02.

Warning Sign:

Ainos Inc revenue per share has been in decline over the past 3 years.

During the past 12 months, the average Revenue Per Share Growth Rate of Ainos was -98.10% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -1.10% per year. During the past 5 years, the average Revenue Per Share Growth Rate was 19.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Ainos's Revenue per Share or its related term are showing as below:

AIMD' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -86.9   Med: -27.1   Max: 282.9
Current: -1.1

During the past 13 years, Ainos's highest 3-Year average Revenue Per Share Growth Rate was 282.90% per year. The lowest was -86.90% per year. And the median was -27.10% per year.

AIMD's 3-Year Revenue Growth Rate is ranked worse than
68.85% of 748 companies
in the Medical Devices & Instruments industry
Industry Median: 7.05 vs AIMD: -1.10

Ainos Revenue per Share Historical Data

The historical data trend for Ainos's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ainos Revenue per Share Chart

Ainos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.02 0.03 0.39 1.29 0.03

Ainos Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 -

Competitive Comparison of Ainos's Revenue per Share

For the Medical Devices subindustry, Ainos's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ainos's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Ainos's PS Ratio distribution charts can be found below:

* The bar in red indicates where Ainos's PS Ratio falls into.



Ainos Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Ainos's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0.122/4.098
=0.03

Ainos's Revenue Per Share for the quarter that ended in Mar. 2024 is calculated as

Revenue Per Share (Q: Mar. 2024 )=Revenue (Q: Mar. 2024 )/Shares Outstanding (Diluted Average) (Q: Mar. 2024 )
=0.021/5.771
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ainos  (NAS:AIMD) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Ainos Revenue per Share Related Terms

Thank you for viewing the detailed overview of Ainos's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Ainos (AIMD) Business Description

Traded in Other Exchanges
N/A
Address
8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low dose oral form.
Executives
Meng Lin Sung officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc 10 percent owner 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei director 10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai director, officer: Chairman, CEO, CFO 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang director 5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang director NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin other: EVP - OPERATIONS 2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu director 9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai director 105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen director 1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen officer: VP, CFO 4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore director 402 FISH HATCHERY ROAD, HAMILTON MT 59840